Nature

Leukaemia articles from across Nature Portfolio

Leukaemia is a type of blood cancer, which starts in blood-forming tissue, such as the bone marrow, and causes large numbers of immature blood cells to be produced and enter the bloodstream. Leukaemia is subdivided into different subtypes according to cellular maturity (acute or chronic) and cell type (lymphocytic or myeloid).

Related Subjects

Latest Research and Reviews

The DNA damage-independent ATM signalling maintains CBP/DOT1L axis in MLL rearranged acute myeloid leukaemia
- Guangming Wang
- Wenjun Zhang
- Aibin Liang
ResearchOpen Access26 Apr 2024 Oncogene
P: 1-17
8-Cl-Ado and 8-NH₂-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia
- Jiamin Guo
- Ralf Buettner
- Steven T. Rosen
ResearchOpen Access20 Apr 2024 Leukemia
P: 1-10
Leukemia circulation kinetics revealed through blood exchange method

A blood exchange system reveals that leukemia cells clear faster in the blood than circulating tumor cells from solid tumors and that clearance rates can vary in response to tumor and treatment status.
- Alex B. Miller
- Felicia H. Rodriguez
- Scott R. Manalis
ResearchOpen Access20 Apr 2024 Communications Biology
Volume: 7, P: 483
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia
- Shinju Iyoda
- Kenichi Yoshida
- Hidemasa Matsuo
Research18 Apr 2024 Leukemia
P: 1-4
Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody
- Sylwia A. Stefańczyk
- Ilona Hagelstein
- Melanie Märklin
ResearchOpen Access18 Apr 2024 Blood Cancer Journal
Volume: 14, P: 67
The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia

Lawson et al. show that genetic inactivation of Phd1 or Phd2 hinders progression of AML and compromises leukemic stem cells. They develop a selective PHD inhibitor IOX5 and show therapeutic efficacy in AML, which can be potentiated with venetoclax.
- Hannah Lawson
- James P. Holt-Martyn
- Kamil R. Kranc
ResearchOpen Access18 Apr 2024 Nature Cancer
P: 1-22

All Research & Reviews

News and Comment

Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL
- Giuseppe Gritti
- Silvia Ferrari
- Alessandro Rambaldi
CorrespondenceOpen Access26 Apr 2024 Blood Cancer Journal
Volume: 14, P: 73
Refined risk stratification helps guiding transplantation choice in adult BCR::ABL1-positive acute lymphoblastic leukemia
- Cheng Wang
- Jianfeng Li
- Jin Wang
CorrespondenceOpen Access24 Apr 2024 Blood Cancer Journal
Volume: 14, P: 71
Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study
- Yifan Shen
- Minyuan Liu
- Yang Xu
Correspondence13 Apr 2024 Bone Marrow Transplantation
P: 1-3
CEBPA bZIP in-frame mutations in acute myeloid leukemia: prognostic and therapeutic implications
- Fenghong Zhang
- Zhen Shen
- Suning Chen
CorrespondenceOpen Access09 Apr 2024 Blood Cancer Journal
Volume: 14, P: 59
Mitigating immortal-time bias: exploring osteonecrosis and survival in pediatric ALL - AALL0232 trial insights
- Shyam Srinivasan
- Swaminathan Keerthivasagam
Comments & Opinion28 Mar 2024 Leukemia
P: 1-2
A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome
- Ray Mun Koo
- Eric Wong
- David S. Ritchie
Correspondence27 Mar 2024 Bone Marrow Transplantation
P: 1-3

All News & Comment

Search

Advanced search

Quick links